Navigation Links
Study shows that CPAP therapy reduces fatigue, increases energy in patients with sleep apnea

This release is also available in Chinese on EurekAlert! Chinese.

DARIEN, IL Patients with obstructive sleep apnea often report that they feel like "a new person" after beginning treatment with continuous positive airway pressure therapy. A new study in the Jan. 1 issue of the journal SLEEP provides objective evidence to support these anecdotal reports, showing that three weeks of CPAP therapy significantly reduced fatigue and increased energy in patients with OSA.

Results of the randomized controlled trial show that CPAP therapy significantly reduced self-reported, mean fatigue scores on two independent measures: from 8.76 at baseline to -0.10 post-treatment on the Multidimensional Fatigue Symptom Inventory Short Form; and from 7.17 at baseline to 4.03 post-treatment on the fatigue-inertia subscale of the Profile of Mood States Short Form. These results indicate that participants were no longer suffering from clinically significant levels of fatigue after the three-week intervention period.

Self-reported energy levels also increased after three weeks of CPAP therapy, with the mean score on the vigor-activity subscale of the Profile of Mood States Short Form increasing significantly from 14.28 at baseline to 16.52 post-treatment. Significant changes in fatigue and energy were not observed in participants who received placebo CPAP.

"This was one of the first double-blind studies of the effects of CPAP on fatigue," said lead author Lianne Tomfohr, graduate research assistant in the joint doctoral program at San Diego State University and the University of California, San Diego. "These results are important, as they highlight that patients who comply with CPAP therapy can find relief from fatigue and experience increases in energy and vigor after a relatively short treatment period."

Further analysis found that CPAP appeared to be especially beneficial for participants who were excessively fatigued or sleepy before treatment. CPAP therapy significantly reduced self-reported daytime sleepiness in this group, with their mean score on the Epworth Sleepiness Scale dropping from 13.0 at baseline to 8.9 post-treatment.

According to the American Academy of Sleep Medicine, OSA is a common sleep-related breathing disorder that affects at least two to four percent of the adult population. OSA occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway. Most people with OSA snore loudly and frequently, and they often experience fatigue and excessive daytime sleepiness.

The treatment of choice for OSA is CPAP therapy, which provides a steady stream of air through a mask that is worn during sleep. This airflow keeps the airway open to prevent pauses in breathing and restore normal oxygen levels.

Tomfohr and a team of UCSD researchers studied 59 adults with a mean age of 48 years. Overnight polysomnography in a sleep lab confirmed that each participant had OSA, which was defined as having an apnea-hypopnea index (AHI) of 10 or more partial reductions (hypopneas) and complete pauses (apneas) in breathing per hour of sleep.

Participants were randomly assigned to receive either therapeutic CPAP or placebo CPAP, and they returned to the sleep lab for a night of either CPAP titration or mock titration. Participants were trained on the use of the equipment and instructed to use it at home each night for three weeks. Questionnaire data were obtained prior to study randomization and after the three-week intervention period.

According to the authors, the mechanisms that underlie the observed changes in fatigue are unclear. They speculate that CPAP may impact fatigue in patients with OSA by reducing inflammation, noting that increases in inflammatory markers in OSA patients have been related to elevated fatigue.


Contact: Emilee McStay
630-737-9700 x9345
American Academy of Sleep Medicine

Related medicine news :

1. Study finds evidence of increased lung cancer risk among tuberculosis patients
2. Urban Wildlife Adopt Not-so-Healthful Human Diet, Study Finds
3. First Impressions of Attractive People Often Correct: Study
4. Love of Possessions Can Run Deep, Study Shows
5. Anesthesiologists Spreading Germs During Surgery: Study
6. Hearing Loss Rising Among Teen Girls, Study Finds
7. Case Western Reserve receives $10M to study retinal disease, develop new treatments
8. Injectable, Oral Birth Control Dont Threaten Glucose, Insulin Levels: Study
9. People Look to Eyes for Signs of Life, Study Finds
10. Obese Drivers at Higher Risk of Death in Car Crashes: Study
11. Mortality rates are an unreliable metric for assessing hospital quality, study finds
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: